EVALUATION OF EFFICACY OF BUSERELIN-DEPO IN PATIENTS WITH LOCALLY ADVANCED AND METHASTATIC PROSTATE CANCER

Our surveillance was performed for 358 patients with locally advanced and disseminated prostate gland cancer who were treated by analogues of LHRH. Patients in group 1 (n = 222) received treatment with a LHRH analogue, and patients in group 2 (n = 136) received treatment with 75 mg Buserelin-depo 3....

Full description

Saved in:

Bibliographic Details
Published in:	Medicinskij sovet no. 6; pp. 98 - 102
Main Authors:	S. V. MISHUGIN, A. A. DROBYAZKO, A. A. MORDOVIN, A. A. GRICKEVICH, I. G. RUSAKOV
Format:	Journal Article
Language:	English Russian
Published:	Remedium Group LLC 01-06-2017
Subjects:	agonists of luteinizing hormone releasing hormone buserelin hormone therapy prostate cancer prostate-specific antigen testosterone
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Our surveillance was performed for 358 patients with locally advanced and disseminated prostate gland cancer who were treated by analogues of LHRH. Patients in group 1 (n = 222) received treatment with a LHRH analogue, and patients in group 2 (n = 136) received treatment with 75 mg Buserelin-depo 3. Experience has shown that the use of the Buserelin-Depot drug results in a regression of the average PSA value: Up to 36.05 ng/ml in 2 months, up to 12.35 ng/ml - in four months, up to 3.3 ng/ml - in six months. The drug ensures a steady decrease in the level of testosterone in the blood serum to the castration level already in a month after the start of treatment, a decrease in prostate gland volume (from 57.3 to 40.45 cc 3 by month 6 of treatment (-29.4%)). A number of patients have experienced a decrease in the need for analgesics and thus an increase in the activity status. The obtained data are comparable to those in the group of patients receiving other analogues of LHRH.
ISSN:	2079-701X 2658-5790
DOI:	10.21518/2079-701X-2017-6-98-102